Early Intervention
Post hoc analysis of the phase III NETTER-1 study shows the benefit of early treatment with LUTATHERA® (lutetium [177Lu] oxodotreotide)1–4
Neuroendocrine tumours (NETs) tend to grow slowly but are often diagnosed late,5 resulting in increased burden, reduced therapeutic options and worse survival outcomes.5–7 Identifying progression is essential to improving patient outcomes, as it provides an opportunity to review treatment.8
Somatostatin receptor subtype 2 expression is greater in low-grade than in high-grade tumours.9 That’s why early administration of LUTATHERA® after first progression could maximise progression-free survival.3
Please explore the benefits of early treatment with LUTATHERA® by clicking through the below material.1–4
This leave piece summarises the results of the NETTER-1 trial, with a focus on LUTATHERA®’s effectiveness in smaller progressive tumours3
1. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:844–60.
2. Lutathera® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. (Accessed October 2023).
3. Strosberg J, Kunz PL, Hendifar A, et al; NETTER-1 study group. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020;47:2372–82.
4. Pavel M, O’Toole D, Costa F, et al. ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.
5. Díez M, Teulé A, Salazar R. Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol. 2013;26:29–36.
6. Keizer AC, Korse TC, Meijer WG, et al. The effect of delay in diagnosis in patients with neuroendocrine tumors. Int J Endocr Oncol. 2016;3:33–9.
7. Uri I and Grozinsky-Glasberg S. Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Clin Diabetes Endocrinol. 2018;4:16.
8. Merino-Casabiel X, Aller J, Arbizu J, et al. Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2018;20:1522–8.
9. Wang Y, Wang W, Jin K, et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13:1165–74.
